Kilitch Drugs (India)'s Q3 FY 2025-26 Quarterly Results
- 12 Feb 2026
Result Summary
- Kilitch Drugs (India) Ltd reported a 0.4% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Dec (Q3 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 4.4%.
- Its expenses for the quarter were up by 7.7% QoQ and 0.2% YoY.
- The net profit decreased 46.4% QoQ and decreased 23.2% YoY.
- The earnings per share (EPS) of Kilitch Drugs (India) Ltd stood at 2.5 during Q3 FY 2025-26.
Financial Statments for Q3 FY 2025-26
Total Income | 55.34 | 55.58 | 57.89 | -0.4% | -4.4% |
Total Expenses | 49.75 | 46.18 | 49.64 | 7.7% | 0.2% |
Profit Before Tax | 5.60 | 9.40 | 8.25 | -40.4% | -32.1% |
Tax | 1.28 | 1.36 | 2.64 | -5.9% | -51.5% |
Profit After Tax | 4.31 | 8.04 | 5.61 | -46.4% | -23.2% |
Earnings Per Share | 2.50 | 4.97 | 3.71 | -49.7% | -32.6% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Kilitch Drugs (India) Ltd is a pharmaceutical company primarily involved in the manufacturing and marketing of pharmaceutical products. The company operates within the pharmaceutical industry and is known for its range of therapeutic products, including those in segments like anti-infectives, gastroenterology, and pain management, among others. Although specific recent developments are not provided, Kilitch Drugs (India) Ltd continues to be a player in the pharmaceutical space, focusing on expanding its product offerings and market reach. It is pertinent to note that additional details regarding its strategic initiatives or recent developments are not available within the scope of this data.
Revenue
The total income for Kilitch Drugs (India) Ltd during Q3FY26 was ₹55.34 crores. When compared quarter-on-quarter (QoQ) to Q2FY26, where the total income was ₹55.58 crores, there is a slight decrease of 0.4%. Year-over-year (YoY) analysis reveals a more significant decrease of 4.4% from Q3FY25, where the total income was ₹57.89 crores. These figures indicate fluctuations in revenue generation over the specified periods. The observed changes in total income over the quarters and the year reflect its performance dynamics within the given timeframe.
Profitability
In Q3FY26, Kilitch Drugs (India) Ltd reported a Profit Before Tax (PBT) of ₹5.60 crores, down from ₹9.40 crores in Q2FY26, marking a 40.4% decline QoQ. Compared to the previous year, Q3FY25's PBT of ₹8.25 crores shows a YoY decline of 32.1%. The Profit After Tax (PAT) for Q3FY26 is ₹4.31 crores, a significant decrease of 46.4% QoQ from ₹8.04 crores in Q2FY26 and a 23.2% decline YoY from ₹5.61 crores in Q3FY25. These numbers reflect the company's profit trends over the specified periods. Earnings Per Share (EPS) for Q3FY26 was ₹2.50, down 49.7% from the previous quarter's ₹4.97 and 32.6% from the previous year's ₹3.71, showcasing the changes in shareholder earnings over time.
Operating Metrics
Total expenses for Kilitch Drugs (India) Ltd in Q3FY26 amounted to ₹49.75 crores, reflecting an increase of 7.7% QoQ from ₹46.18 crores in Q2FY26 and a marginal increase of 0.2% YoY from ₹49.64 crores in Q3FY25. The tax expense for Q3FY26 was ₹1.28 crores, which shows a 5.9% decline QoQ from ₹1.36 crores in Q2FY26 and a significant decrease of 51.5% YoY from ₹2.64 crores in Q3FY25. These operational metrics provide insights into the company's cost management and tax obligations over the examined periods. The trends in these operational figures are crucial for understanding the company's financial operations and cost structure dynamics.